Riskpilot← Back to searchSign inGet full accessNutrinovate AB
ABActiveOrg 5590245113Gillinge 55 Hus BResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20150 employees
Revenue 2024
SEK 1,6M
-35% vs 2023
EBITDA margin
-64.1%
+54% vs 2023
Equity ratio
49.6%
Financial strength
Net profit 2024
SEK -1,3M
+57% vs 2023
| Revenue | SEK 1,6M | -35% |
| EBITDA | SEK -1M | +54% |
| Net profit | SEK -1,3M | +57% |
| Total assets | SEK 878K | -57% |
| Equity | SEK 436K | +121% |
| Employees | 0 | — |
Legal name
Nutrinovate AB
Org number
5590245113
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
28 augusti 2015
Share capital
SEK 64 383
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna suppleanten
Company purpose
Aktiebolaget ska bedriva forskning och utveckling inom det medicinska området, marknadsföra och försälja medicinska tjänster och produkter ävensom idka annan därmed förenlig verksamhet.
Address
Gillinge 55 Hus B
Phone
+468334060
Email
lars.bystrom@fftmedical.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 2 494 | 4 221 | 5 551 | 16 547 | 10 295 | 3 983 | 2 452 | 1 597 |
| Staff expenses | — | — | — | — | — | — | — | −383 | −670 |
| EBITDA | −5 979 | −8 042 | −8 767 | −12 955 | −1 580 | −3 655 | −3 356 | −2 228 | −1 023 |
| Depreciation & amort. | −417 | −866 | −1 102 | −798 | −791 | −326 | −256 | −255 | −240 |
| EBIT | −6 396 | −8 908 | −9 869 | −13 753 | −2 371 | −3 981 | −3 612 | −2 483 | −1 263 |
| Net financials | 1 | −2 | −13 | −22 | −39 | −61 | −38 | −425 | 1 |
| Profit before tax | −6 396 | −8 909 | −9 882 | −13 775 | −2 410 | −4 042 | −3 650 | −2 908 | −1 262 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | — |
| Net profit | −6 396 | −8 909 | −9 882 | −13 775 | −2 410 | −4 042 | −3 650 | −2 908 | −1 262 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 18 105 | 8 488 | 10 591 | 15 564 | 16 761 | 9 796 | 4 882 | 2 061 | 878 |
| Equity | 15 038 | 6 470 | 8 234 | 13 207 | 10 797 | 6 755 | 3 105 | 197 | 436 |
| Long-term debt | 1 990 | 0 | 0 | 0 | 0 | 0 | 0 | — | 100 |
| Short-term debt | 1 077 | 2 018 | 2 357 | 2 357 | 5 964 | 3 041 | 1 777 | 1 864 | 342 |
| Total debt | 3 067 | 2 018 | 2 357 | 2 357 | 5 964 | 3 041 | 1 777 | 1 864 | 442 |
EBITDA margin
-64.1%
This company
15.8%
Market median
-506% vs market
20162024
Equity ratio
49.6%
This company
38.2%
Market median
+30% vs market
20162024
Return on equity
-289.7%
This company
18.4%
Market median
-1674% vs market
20162024
Net profit margin
-79.0%
This company
8.1%
Market median
-1075% vs market
20162024
Asset turnover
1.82×
This company
1.12×
Market median
+62% vs market
20162024
Debt / equity
1.01×
This company
0.62×
Market median
-63% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-08-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PM Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
SM External Signatory | External Signatory | 2022 | — | — |
LE | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2025 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
FFT Medical AB | Company | 72.0% | 72.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
FFT Medical AB
Nutrinovate AB Board members of Nutrinovate AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Pär Magnus Nilsson Vall | Chief Executive Officer | 0 companies |
| Stig Mikael Lindblad | External Signatory | 0 companies |
| Lars Erik Ingemar Lidgren | Audit | 0 companies |
| Thomas Johan Ekerborn | Deputy Board Member | 0 companies |
| Hans Gustaf Lindroth | Deputy Board Member | 0 companies |
| Charles Scott Boyer | Board of Directors | 0 companies |
| Lars Gunnar Johan Byström | Chairman | 0 companies |
| Nils Patrik Johansson | Board of Directors | 0 companies |